Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT03889639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary Objectives: * To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures. * To evaluate the safety and tolerability of SAR442168.
Study identification
- NCT ID
- NCT03889639
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Interventions
- SAR442168 Drug
- Placebo Drug
- Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2019
- Primary completion
- Jan 1, 2020
- Completion
- Jan 1, 2020
- Last update posted
- Sep 16, 2025
2019 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 8400005 | Cullman | Alabama | 35058 | — |
| Investigational Site Number 8400002 | Maitland | Florida | 32761 | — |
| Investigational Site Number 8400004 | Sunrise | Florida | 33351 | — |
| Investigational Site Number 8400009 | Tampa | Florida | 33612 | — |
| Investigational Site Number 8400007 | Savannah | Georgia | 31406 | — |
| Investigational Site Number 8400001 | Northbrook | Illinois | 60062 | — |
| Investigational Site Number 8400008 | Dayton | Ohio | 45417 | — |
| Investigational Site Number 8400006 | Westerville | Ohio | 43081 | — |
| Investigational Site Number 8400003 | Knoxville | Tennessee | 37922 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03889639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2025 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03889639 live on ClinicalTrials.gov.